Tokyo, Aug 23, 2007 (JCN Newswire) - Teijin Pharma Limited (“Teijin"; headquarters: Chiyoda-ku, Tokyo; President: Shigeo Ohyagi) and Chugai Pharmaceutical Co., Ltd. (“Chugai"; headquarters: Chuo-ku, Tokyo; President and CEO: Osamu Nagayama) announced today that they have concluded a collaboration agreement to develop an anti-diabetic drug ITM-077 (Ipsen development code: BIM 51077, Roche and Chugai development code: R1583) in Japan originated by Ipsen (stock code Euronext: IPN), an innovation driven international specialty pharmaceutical group (“Ipsen"; headquarters: Paris, France; Chairman and CEO: Jean-Luc Belingard).
